-
Je něco špatně v tomto záznamu ?
CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)
M. Drosslerova, M. Sterclova, A. Taskova, V. Hytych, E. Richterova, M. Bruzova, M. Spunda, M. Komarc, M. Koziar Vasakova
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
PubMed
36628560
DOI
10.5507/bp.2022.050
Knihovny.cz E-zdroje
- MeSH
- biologické markery MeSH
- chemokin CCL2 MeSH
- chemokin CCL8 MeSH
- chemokin CXCL12 MeSH
- chemokiny MeSH
- lidé MeSH
- nádory plic * chirurgie patologie MeSH
- nemalobuněčný karcinom plic * chirurgie patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diagnosis differ from healthy controls and reflect the extent of NSCLC. AIMS: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in the plasma of patients with resectable NSCLC to those without cancer. To determine whether the chemokine concentrations differ relative to the stage of disease. METHODS: Sixty-nine patients undergoing surgery for proven/suspected NSCLC were enrolled. They underwent standard diagnostic and staging procedures to determine resectability, surgery was performed. Forty-two patients were diagnosed with NSCLC, while 27patients had benign lung lesions and functioned as the control group. Chemokine concentrations in peripheral blood were assessed using ELISA. Parametric statistics were used for the analysis of results. RESULTS: There were no differences in plasma chemokine concentrations in NSCLC patients compared to controls. CXCL12 concentrations correlated positively with tumor extent expressed as clinical stage, (mean values: stage I 5.08 ng/mL, SEM 0.59; stage II and IIIA 7.82 ng/mL; SEM 1.06; P=0.022). Patients with NSCLC stages II+IIIA had significantly higher CXCL12 concentrations than controls (mean values: stage II+IIIA 7.82 ng/mL; SEM 1.06; controls 5.3 ng/mL; SEM 0.46; P=0.017). CONCLUSION: CXCL12 was related to tumor growth and could potentially be used as a biomarker of advanced disease.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23022198
- 003
- CZ-PrNML
- 005
- 20250228133210.0
- 007
- ta
- 008
- 240104s2023 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2022.050 $2 doi
- 035 __
- $a (PubMed)36628560
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Drosslerova, Marie $u Department of Respiratory Medicine, 1st Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
- 245 10
- $a CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC) / $c M. Drosslerova, M. Sterclova, A. Taskova, V. Hytych, E. Richterova, M. Bruzova, M. Spunda, M. Komarc, M. Koziar Vasakova
- 520 9_
- $a BACKGROUND: Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diagnosis differ from healthy controls and reflect the extent of NSCLC. AIMS: To compare chemokine concentrations (CCL2, CCL8, CXCL12) in the plasma of patients with resectable NSCLC to those without cancer. To determine whether the chemokine concentrations differ relative to the stage of disease. METHODS: Sixty-nine patients undergoing surgery for proven/suspected NSCLC were enrolled. They underwent standard diagnostic and staging procedures to determine resectability, surgery was performed. Forty-two patients were diagnosed with NSCLC, while 27patients had benign lung lesions and functioned as the control group. Chemokine concentrations in peripheral blood were assessed using ELISA. Parametric statistics were used for the analysis of results. RESULTS: There were no differences in plasma chemokine concentrations in NSCLC patients compared to controls. CXCL12 concentrations correlated positively with tumor extent expressed as clinical stage, (mean values: stage I 5.08 ng/mL, SEM 0.59; stage II and IIIA 7.82 ng/mL; SEM 1.06; P=0.022). Patients with NSCLC stages II+IIIA had significantly higher CXCL12 concentrations than controls (mean values: stage II+IIIA 7.82 ng/mL; SEM 1.06; controls 5.3 ng/mL; SEM 0.46; P=0.017). CONCLUSION: CXCL12 was related to tumor growth and could potentially be used as a biomarker of advanced disease.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nemalobuněčný karcinom plic $x chirurgie $x patologie $7 D002289
- 650 12
- $a nádory plic $x chirurgie $x patologie $7 D008175
- 650 _2
- $a chemokiny $7 D018925
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a chemokin CCL8 $7 D054412
- 650 _2
- $a chemokin CCL2 $7 D018932
- 650 _2
- $a chemokin CXCL12 $7 D054377
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Šterclová, Martina, $u Department of Respiratory Medicine, 1st Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic $d 1979- $7 xx0108032
- 700 1_
- $a Tašková, Alice, $u Department of Thoracic Surgery, Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic $d 1975- $7 pna2014841693
- 700 1_
- $a Hytych, Vladislav, $u Department of Thoracic Surgery, Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic $d 1954- $7 xx0077545
- 700 1_
- $a Richterova, Eva $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
- 700 1_
- $a Bruzova, Magdalena $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
- 700 1_
- $a Špunda, Miloslav, $u Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska 1, 120 00 Prague 2, Czech Republic $d 1942- $7 nlk19990074145
- 700 1_
- $a Komarc, Martin $u Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Salmovska 1, 120 00 Prague 2, Czech Republic $7 pna20191026198
- 700 1_
- $a Koziar Vasakova, Martina $u Department of Respiratory Medicine, 1st Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 00 Prague 4, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 4 (2023), s. 335-339
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36628560 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y - $z 0
- 990 __
- $a 20240104 $b ABA008
- 991 __
- $a 20250228133203 $b ABA008
- 999 __
- $a ok $b bmc $g 2276361 $s 1208642
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 167 $c 4 $d 335-339 $e 20230109 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
- LZP __
- $b NLK116 $a Pubmed-20240104